Thomas O. Daniel

CIK: 0001538894

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

ASPE

Aspen Neuroscience, Inc.

Director

GOSS

Gossamer Bio, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (3 total)

GOSS
Gossamer Bio, Inc.
Sep 23, 2026
Award(A)
Stock Option (Right to Buy)
Direct
10K shares-
GOSS
Gossamer Bio, Inc.
Jun 4, 2026
Award(A)
Stock Option (Right to Buy)
Direct
115K shares-
GOSS
Gossamer Bio, Inc.
Jun 25, 2025
Award(A)
Stock Option (Right to Buy)
Direct
115K shares-

		Type	Shares	Price		Ownership
Sep 23, 2026	GOSS Gossamer Bio, Inc.	Award(A) Stock Option (Right to Buy)	10,000	-	-	Direct
Jun 4, 2026	GOSS Gossamer Bio, Inc.	Award(A) Stock Option (Right to Buy)	115,000	-	-	Direct
Jun 25, 2025	GOSS Gossamer Bio, Inc.	Award(A) Stock Option (Right to Buy)	115,000	-	-	Direct

1-3 of 3 transactions

About Daniel Thomas O

Daniel Thomas O (SEC CIK 0001538894) files insider reports with the SEC as Director of Aspen Neuroscience, Inc. (ASPE) and Director of Gossamer Bio, Inc. (GOSS).

Signal8 holds 4 ownership filings by Daniel Thomas O (1 Form 3, 3 Form 4), filed between Jun 26, 2025 and Oct 29, 2026. Those filings report 3 transactions, from Jun 25, 2025 to Sep 23, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Daniel Thomas O's filings is in SAN DIEGO, CA.

Recent filings by Daniel Thomas O

Sep 23, 2026: Grant or award of GOSS derivative securities (Form 4, code A).
Jun 4, 2026: Grant or award of GOSS derivative securities (Form 4, code A).
Jun 25, 2025: Grant or award of GOSS derivative securities (Form 4, code A).

Other insiders filing for Aspen Neuroscience, Inc. (ASPE)

ARCH Venture Fund X, L.P., 10% Owner
ARCH Venture Partners XIV, L.P., 10% Owner
Spaventa Andrew, Director
Hasnain Faheem, Executive Chair
ORBIMED ADVISORS LLC, Director
Boerneke Jeffrey Lee, General Counsel and Secretary

How to read Form 4 transaction codes